FAQ on Lantern Pharma Inc.'s LP-184 Preclinical Success in Pediatric Brain Cancer ATRT
Summary
Lantern Pharma Inc. (NASDAQ: LTRN) has reported promising preclinical results for LP-184 in treating atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer, showing significant survival improvements in mouse models and plans for a pediatric Phase I trial by late 2025 or early 2026.
What is LP-184 and what has it achieved in preclinical trials?
LP-184 is a drug candidate by Lantern Pharma that has shown significant preclinical success in treating atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer, by improving survival rates in mouse models and demonstrating potent anti-tumor activity across ATRT subtypes.
Why is the success of LP-184 in preclinical trials significant?
The success is significant because ATRT is a rare and aggressive pediatric brain cancer with currently no effective, low-toxicity treatments, and LP-184 has shown a 345% increase in median survival in one mouse model, highlighting its potential as a novel therapy.
How does LP-184 work against ATRT?
LP-184 works by demonstrating potent anti-tumor activity across ATRT subtypes, high blood-brain barrier penetration, and a favorable safety profile, targeting cancers driven by SMARCB1 gene inactivation.
Who presented the preclinical data for LP-184?
Dr. Eric Raabe of Johns Hopkins presented the data at the Society for Neuro-Oncology’s Pediatric Neuro-Oncology Conference.
When is Lantern Pharma planning to launch a pediatric Phase I trial for LP-184?
Lantern Pharma plans to launch a pediatric Phase I trial in late 2025 or early 2026, following the completion of its ongoing adult trial and pending consortium approvals.
What is Lantern Pharma’s approach to drug discovery and development?
Lantern Pharma uses an AI and machine learning platform, RADR®, which leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to accelerate the development of oncology drug candidates, reducing the time and cost significantly.
What are the implications of LP-184’s success for cancer treatment?
The success of LP-184 could provide a life-changing therapy for hundreds of thousands of cancer patients, especially those with ATRT and other cancers lacking effective treatments, with a combined annual market potential of over $15 billion USD.
Where can I find more information about Lantern Pharma and its research?
More information can be found on Lantern Pharma’s website at https://www.lanternpharma.com/ and the full press release at https://ibn.fm/uOUKi.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 110935